Literature DB >> 1412604

Interaction between fluvoxamine and imipramine/desipramine in four patients.

E Spina1, G M Campo, A Avenoso, M A Pollicino, A P Caputi.   

Abstract

We describe four patients in whom the addition of fluvoxamine (100 mg/day) to the treatment with imipramine or desipramine (100-150 mg/day) resulted in a dramatic increase in the plasma concentrations of the tricyclic antidepressants associated with adverse effects. These observations indicate that fluvoxamine inhibits both the demethylation of imipramine and, possibly to a lesser extent, the hydroxylation of desipramine. The combination of fluvoxamine with tricyclic antidepressants should be avoided whenever possible.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1412604     DOI: 10.1097/00007691-199206000-00004

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  20 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 2.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

3.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.

Authors:  K Kobayashi; M Nakajima; K Chiba; T Yamamoto; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 4.  Clinically significant drug interactions with antidepressants in the elderly.

Authors:  Edoardo Spina; Maria Gabriella Scordo
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Non-competitive inhibition of clomipramine N-demethylation by fluvoxamine.

Authors:  S Härtter; M Arand; F Oesch; C Hiemke
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

Review 6.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2.

Authors:  K Brøsen
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 7.  Fluvoxamine. A review of global drug-drug interaction data.

Authors:  W Wagner; E W Vause
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 8.  Overview of the pharmacokinetics of fluvoxamine.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

9.  Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.

Authors:  L Bertilsson; J A Carrillo; M L Dahl; A Llerena; C Alm; U Bondesson; L Lindström; I Rodriguez de la Rubia; S Ramos; J Benitez
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

Review 10.  Antidepressant toxicity and the need for identification and concentration monitoring in overdose.

Authors:  B M Power; L P Hackett; L J Dusci; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.